

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/22/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/761,530	01/21/2004	Dwight D. Koeberl	5405.280	3856
20792	7590 06/22/2006		EXAMINER	
MYERS BIGEL SIBLEY & SAJOVEC			PATTERSON, CHARLES L JR	
PO BOX 3742			ART UNIT	PAPER NUMBER
RALEIGH, N	C 2/02/		1652	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Community	10/761,530	KOEBERL ET AL.				
Office Action Summary	Examiner	Art Unit				
	Charles L. Patterson, Jr.	1652				
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE!	N. nely filed the mailing date of this communication.				
Status						
1) Responsive to communication(s) filed on						
	 s action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-72</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.	·					
7) Claim(s) is/are objected to.	_					
8) Claim(s) 1-72 are subject to restriction and/or	election requirement					
	ciection requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) Notice of Informal Patent Application (PTO-152)						
Paper No(s)/Mail Date 6) Other:						

Application/Control Number: 10/761,530

Art Unit: 1652

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-18, 21-29 drawn to a nucleic acid encoding a chimeric polypeptide, a vector containing the nucleic acid, a pharmaceutical composition comprising the nucleic acid, a cell containing the nucleic acid, a method of delivering the nucleic acid to the cell or producing an α -glucosidase, classified in class 536, subclass 23.1, class 435, subclass 320.1, 252.3, class 514, subclass 44.

Page 2

- II. Claims 19-20, drawn to a chimeric polypeptide, classified in class 435, subclass 201.
- III. Claim 30-37, drawn to a method of treating a deficiency of lysosomal polypeptide in a subject comprising administering the nucleic acid of a cell containing the nucleic acid of group I, classified in class 514, subclass 44.
- IV. Claims 38-64, drawn to a nucleic acid encoding a lysosomal α -glucosidase comprising the coding region and a 3' untranslated region comprising a deletion of at least 25 nucleotides that increases α -glucosidase production, a vector containing the nucleic acid, a pharmaceutical formulation comprising the nucleic acid, a cell comprising the nucleic acid, a method of delivering a nucleic acid to a cell and a method of producing lysosomal α -glucosidase by using cells containing the nucleic acid, classified in class 435, subclass 320.1, 252.3 and class 536, subclass 23.2.
- V. Claims 65-72, drawn to a method of treating an α -glucosidase deficiency in a subject comprising administering the nucleic acid

Art Unit: 1652

or a cell containing the nucleic acid of group IV, classified in class 514, subclass 44.

The inventions are independent or distinct, each from the other because:

Groups I and II are drawn to different chemical compounds that are patentably distinct.

Groups I and IV are drawn to two different nucleic acids, the second containing a deletion in the 3' untranslated region that effect the level of production of the enzyme, and are therefore patentably distinct.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product as claimed can be used in a materially different process such as to cleave a sugar not related to the treatment method of Invention III.

Inventions IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product as claimed can be used in a materially different process such as to cleave a sugar not related to the treatment method of Invention V.

Art Unit: 1652

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Charles L. Patterson, Jr

Page 4

Primary Examiner Art Unit 1652

Patterson June 12, 2006